title: [Suppression of VEGF protein expression by arctigenin in oral squamous cell carcinoma].
abstract: OBJECTIVE
  To observe arctigenin's inhibitory effect on oral squamous cell carcinoma, and explore the possible mechanism.
  
  
  METHODS
  The expression of VEGF in 32 cases of oral squamous cell cancer and 20 adjacent tissue specimen were detected with immunohistochemistry. Human nude mouse transplantation tumor model of oral squamous cell cancer was prepared with HSC-3 cells line. Transplanted tumor growth and VEGF expression in transplanted tumor tissues were assayed after treatment with arctigenin. One-way ANOVA was used for comparison between groups with SPSS 16.0 software package.
  
  
  RESULTS
  Compared with the adjacent tissue, immunohistochemical staining score of VEGF was significantly higher (P<0.01) in oral squamous cell carcinoma tissues. After treatment with arctigenin, the growth of oral squamous cell transplanted tumors in nude mouse was inhibited (P<0.05), and decreased weight in end point of observation was noted (P<0.05). There were significant differences between high dose group and low dose group (P<0.05). Compared with the nude mouse model group, the optical density of VEGF staining was significantly lower in arctigenin group (P<0.05). There were significant differences between high dose group and low dose group (P<0.05).
  
  
  CONCLUSIONS
  Arctigenin can dose-dependently inhibit the growth of oral squamous cell carcinomas, and this effect may be related to down regulation of VEGF expression.
authors.affiliation: Department of Dentistry, The First Affiliated Hospital of Dalian Medical University. Dalian 116011;China.E-mail:dl_pugr@126.com.
authors.forename: Guang-rui
authors.initials: GR
authors.lastname: Pu
authors.forename: Fa-yu
authors.initials: FY
authors.lastname: Liu
authors.forename: Bo
authors.initials: B
authors.lastname: Wang
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002294:Carcinoma, Squamous Cell / Q000378:metabolism*; D015536:Down-Regulation; D005663:Furans / Q000494:pharmacology*; D006801:Humans; D007150:Immunohistochemistry; D017705:Lignans / Q000494:pharmacology*; D051379:Mice; D008819:Mice, Nude; D009062:Mouth Neoplasms / Q000378:metabolism*; D009368:Neoplasm Transplantation; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D005663:Furans; D017705:Lignans; D042461:Vascular Endothelial Growth Factor A; C071942:arctigenin